Aditxt subsidiary Persanta engages Dominary Securities for IPO

The company states: “Aditxt (ADTX) announced that its subsidiary, Pearsanta has engaged Dominari Securities LLC as lead underwriter for Pearsanta’s planned initial public offering. The proposed IPO, advised by Dominari Securities, is intended to support Pearsanta’s U.S. and international commercial launch efforts and further advance its Mitomic(R) Technology platform for early cancer detection and diagnosis. Pearsanta is developing a non-invasive blood-based test designed to detect cancer at earlier stages when treatment outcomes are more favorable. The Company’s proprietary Mitomic(R) Technology leverages mitochondrial DNA deletions as biomarkers for disease detection, providing a unique approach to identifying malignancies. We believe that Pearsanta’s biomarker portfolio covers many high-clinical need cancers, with potential applications outside oncology. As Pearsanta prepares for its planned IPO targeted for the second half of 2025, the Company is focused on advancing its commercialization strategy. IPO proceeds are intended to be used to fund the U.S. launch of its Laboratory Developed Tests (LDTs) for early cancer detection and drive global commercialization through distribution partnerships and key international regulatory approvals.”